BC Innovations | Jun 4, 2019
Distillery Therapeutics

Inhibiting CB1 for alcohol addiction

DISEASE CATEGORY: Neurology INDICATION: Addiction Studies in mice suggest inhibiting CB1 could help treat alcohol addiction. In a mouse model of alcohol addiction, an shRNA targeting CB1 reduced alcohol preference compared with a scrambled shRNA....
BC Innovations | Jan 23, 2019
Distillery Therapeutics

Neurology

INDICATION: Depression Mouse studies suggest agonizing CB1 could help treat depression. In a mouse model of depression, optogenetic activation of synaptic circuits involving cholecystokinin (CCK)-positive neurons in the basal lateral amygdala and dopamine D2 receptor...
BC Innovations | Oct 18, 2018
Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
BC Week In Review | Sep 21, 2018
Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...
Items per page:
1 - 4 of 4